Acadian Asset Management
CNTX icon

Acadian Asset Management’s Context Therapeutics CNTX Stock Holding History

Acadian Asset Management’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$559K Buy
+1,010,904
New +$2.05M ﹤0.01% 1414
2025
Q1 		– Sell
-16,668
Closed -$17K – 1648
2024
Q4 		$17K Buy
+16,668
New +$28.8K ﹤0.01% 1550

Other funds holding CNTX

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Acadian Asset Management's CNTX Position: Q2 2026 in Review

Acadian Asset Management opened a new position in Context Therapeutics (CNTX) in Q2 2026: 1,010,904 shares worth $559K. The stake represents ﹤0.01% of the portfolio and ranks #1414 among its holdings. This is a return to the name: Acadian Asset Management previously reported a position in CNTX as recently as Q4 2024.

Acadian Asset Management first reported a position in CNTX in Q4 2024 and has held it in 2 quarters since. 79 funds tracked by Wall St. Rank hold CNTX as of Q2 2026.

  • Acadian Asset Management held 1,010,904 shares of Context Therapeutics worth $559K as of Q2 2026.
  • Context Therapeutics was a new Acadian Asset Management position in Q2 2026.
  • Context Therapeutics made up ﹤0.01% of Acadian Asset Management's portfolio in Q2 2026, its #1414 holding.
  • Acadian Asset Management first reported a position in Context Therapeutics in Q4 2024 and has held it in 2 quarters since.
  • 79 funds tracked by Wall St. Rank held Context Therapeutics as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.